|
HRP20220766T1
(hr)
|
2012-11-08 |
2022-09-16 |
Bristol-Myers Squibb Company |
Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
|
|
CA2890935A1
(en)
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
|
|
AU2013341200A1
(en)
*
|
2012-11-08 |
2015-07-02 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyridyl compounds useful as kinase modulators
|
|
AR094537A1
(es)
|
2013-11-07 |
2015-08-12 |
Bristol Myers Squibb Co |
COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
|
|
ES2702126T3
(es)
|
2013-12-10 |
2019-02-27 |
Bristol Myers Squibb Co |
Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
|
WO2016022626A1
(en)
*
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
CN107849039B
(zh)
|
2015-06-24 |
2020-07-03 |
百时美施贵宝公司 |
经杂芳基取代的氨基吡啶化合物
|
|
EP3313844B1
(en)
|
2015-06-24 |
2020-08-26 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
TW201713655A
(zh)
|
2015-06-24 |
2017-04-16 |
必治妥美雅史谷比公司 |
經雜芳基取代之胺基吡啶化合物
|
|
WO2017089985A1
(en)
*
|
2015-11-26 |
2017-06-01 |
Novartis Ag |
Diamino pyridine derivatives
|
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
|
CN110300590A
(zh)
|
2016-10-21 |
2019-10-01 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
MA48602A
(fr)
*
|
2016-12-13 |
2020-03-18 |
Bristol Myers Squibb Co |
Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha
|
|
AU2018230737B2
(en)
|
2017-03-08 |
2022-09-22 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
LT3601268T
(lt)
*
|
2017-03-30 |
2021-05-25 |
Bristol-Myers Squibb Company |
6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
|
|
CA3062602A1
(en)
|
2017-05-11 |
2018-11-15 |
Bristol-Myers Squibb Company |
Thienopyridines and benzothiophenes useful as irak4 inhibitors
|
|
TWI776810B
(zh)
*
|
2017-05-12 |
2022-09-11 |
瑞士商諾華公司 |
新穎二胺基吡啶衍生物
|
|
IL317854A
(en)
|
2017-07-28 |
2025-02-01 |
Takeda Pharmaceuticals Co |
TYK2 inhibitors and their uses
|
|
MY202167A
(en)
*
|
2017-11-21 |
2024-04-12 |
Bristol Myers Squibb Co |
Sulfone pyridine alkyl amide-substituted heteroaryl compounds
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
CN112118837B
(zh)
|
2018-02-13 |
2024-07-09 |
罗格斯新泽西州立大学 |
抗菌剂：o-烷基氘化派洛宁
|
|
US12209082B2
(en)
|
2018-02-13 |
2025-01-28 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: soluble salts and aqueous formulations of pyronins
|
|
US11572337B2
(en)
|
2018-03-06 |
2023-02-07 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: arylalkylcarboxamido phloroglucinols
|
|
TW201940483A
(zh)
|
2018-03-12 |
2019-10-16 |
美商艾伯維有限公司 |
酪胺酸激酶２介導的傳訊之抑制劑
|
|
JP7485609B2
(ja)
*
|
2018-03-22 |
2024-05-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
KR102858043B1
(ko)
*
|
2018-10-30 |
2025-09-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CA3126034A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
KR102943760B1
(ko)
*
|
2019-01-28 |
2026-03-26 |
장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 |
피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021011724A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
JP7620611B2
(ja)
|
2019-07-18 |
2025-01-23 |
ブリストル－マイヤーズ スクイブ カンパニー |
ＩＲＡＫ４阻害剤として有用なピラゾロ［３，４－ｄ］ピロロ［１，２－ｂ］ピリダジニル化合物
|
|
JP7573596B2
(ja)
|
2019-07-23 |
2024-10-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
|
|
EP4010317B1
(en)
|
2019-08-06 |
2024-06-19 |
Bristol-Myers Squibb Company |
Bicyclic heterocyclic compounds useful as irak4 inhibitors
|
|
CN114206874B
(zh)
|
2019-08-13 |
2024-08-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的双环杂芳基化合物
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
EP4100408B1
(en)
|
2020-02-03 |
2024-02-28 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
WO2021158495A1
(en)
|
2020-02-03 |
2021-08-12 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
|
|
CN111202068A
(zh)
*
|
2020-03-11 |
2020-05-29 |
西北农林科技大学 |
N-苄基苯甲酰胺类化合物及其制备方法与用途
|
|
US20230295119A1
(en)
*
|
2020-04-14 |
2023-09-21 |
Gossamer Bio Services, Inc. |
Substituted pyridines for the treatment of inflammatory diseases
|
|
KR20230004771A
(ko)
|
2020-04-28 |
2023-01-06 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
EP4194450A4
(en)
*
|
2020-08-07 |
2024-10-30 |
Pharmablock Sciences (Nanjing), Inc. |
CDK9 INHIBITOR AND USE THEREOF
|
|
CN114181257B
(zh)
*
|
2020-09-14 |
2025-02-14 |
四川科伦博泰生物医药股份有限公司 |
吡啶类化合物，包含其的药物组合物，其制备方法及其用途
|
|
EP4232425A4
(en)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1 inhibitors and uses thereof
|
|
WO2022133046A2
(en)
*
|
2020-12-16 |
2022-06-23 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US12668594B2
(en)
|
2020-12-23 |
2026-06-30 |
Sudo Biosciences Limited |
TYK2 inhibitors and uses thereof
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN117242072A
(zh)
*
|
2021-02-19 |
2023-12-15 |
苏多生物科学有限公司 |
Tyk2抑制剂及其用途
|
|
CN117377669A
(zh)
*
|
2021-02-19 |
2024-01-09 |
苏多生物科学有限公司 |
Tyk2抑制剂及其用途
|
|
TW202302583A
(zh)
*
|
2021-02-19 |
2023-01-16 |
英商蘇多生物科學有限公司 |
Ｔｙｋ２抑制劑及其用途
|
|
CN117120440A
(zh)
*
|
2021-02-19 |
2023-11-24 |
苏多生物科学有限公司 |
Tyk2抑制剂及其用途
|
|
WO2022175745A1
(en)
*
|
2021-02-19 |
2022-08-25 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
IL305119A
(en)
|
2021-02-19 |
2023-10-01 |
Sudo Biosciences Ltd |
Tyk2 inhibitors and uses thereof
|
|
KR20230159421A
(ko)
|
2021-02-19 |
2023-11-21 |
수도 바이오사이언시즈 리미티드 |
Tyk2 억제제 및 이의 용도
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
KR20240008338A
(ko)
*
|
2021-05-14 |
2024-01-18 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 헤테로시클릭 화합물
|
|
KR20240111312A
(ko)
|
2021-10-25 |
2024-07-16 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Tyk2 분해제 및 이의 용도
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
WO2023108536A1
(en)
*
|
2021-12-16 |
2023-06-22 |
Lynk Pharmaceuticals Co. Ltd. |
Tyk2 inhibitors and compositions and methods thereof
|
|
TW202339749A
(zh)
*
|
2021-12-16 |
2023-10-16 |
大陸商凌科藥業有限公司 |
Ｔｙｋ２抑制劑及其組合物和方法
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
CN116693449A
(zh)
*
|
2022-03-04 |
2023-09-05 |
上海致根医药科技有限公司 |
用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
|
|
CA3249626A1
(en)
*
|
2022-04-19 |
2023-10-26 |
Blueprint Medicines Corporation |
KIT INHIBITORS
|
|
WO2023227946A1
(en)
*
|
2022-05-27 |
2023-11-30 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
EP4565569A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
JP2025539787A
(ja)
*
|
2022-11-16 |
2025-12-09 |
ヴァーンウィ セラピューティクス，インコーポレイテッド |
Ｔｙｋ２阻害剤
|
|
JP2026519238A
(ja)
*
|
2023-06-02 |
2026-06-12 |
アイディーアールエックス、インコーポレイテッド |
がんの処置における使用のためのｋｉｔ阻害剤を含む組合せ治療
|
|
EP4780462A1
(en)
|
2023-09-21 |
2026-07-29 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|